CN Patent

CN102406646B — 芳基脲衍生物用于制备治疗移植排斥药物的用途

Assigned to New Founder Holdings Development Co ltd · Expires 2015-09-09 · 11y expired

What this patent protects

本发明公开了一种芳基脲衍生物用于制备治疗移植排斥药物的用途，所述芳基脲衍生物为1-(4-(三氟甲基)-苯基)-3-(3-(6-(1-甲基-4-吡唑基)-4-嘧啶氧基)-6-氟-苯基)脲。本发明化合物能够明显减轻机体对移植器官的排斥反应，改善移植器官功能，可以用于制备防治器官移植免疫排斥反应的药物，特别是用于制备防治肾移植、肝移植或心脏移植手术后免疫排斥反应的药物。

USPTO Abstract

本发明公开了一种芳基脲衍生物用于制备治疗移植排斥药物的用途，所述芳基脲衍生物为1-(4-(三氟甲基)-苯基)-3-(3-(6-(1-甲基-4-吡唑基)-4-嘧啶氧基)-6-氟-苯基)脲。本发明化合物能够明显减轻机体对移植器官的排斥反应，改善移植器官功能，可以用于制备防治器官移植免疫排斥反应的药物，特别是用于制备防治肾移植、肝移植或心脏移植手术后免疫排斥反应的药物。

Drugs covered by this patent

Patent Metadata

Patent number
CN102406646B
Jurisdiction
CN
Classification
—
Expires
2015-09-09
Drug substance claim
No
Drug product claim
No
Assignee
New Founder Holdings Development Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.